OpenAI researcher Miles Wang in talks to launch AI drug startup

In short: TechCrunch reports that OpenAI researcher Miles Wang plans to leave the company to start an AI drug discovery startup and is in talks to raise funding.

What happened

Miles Wang, a researcher at OpenAI, is planning to launch a new startup focused on drug discovery, according to TechCrunch. Drug discovery is the early work of finding or improving medicines.

Sources told TechCrunch that Wang is discussing raising about $200 million and that the startup could be valued at around $2 billion. A valuation is the price investors put on a company on paper, like an estimate of what it is worth if you sold it today. The sources also said venture firm Lightspeed is in talks to lead the funding round, but the deal is not final and details could change.

Wang disputed TechCrunch’s specific funding figures and how it described the company, but he did not provide alternative numbers. Lightspeed did not respond to a request for comment.

TechCrunch also reports that the company may use AI models, meaning computer systems trained to spot patterns, to find new uses for existing drugs. This includes drugs that already have FDA safety approval and possibly drugs that failed for one purpose but could work for another. It is a bit like finding a new recipe for ingredients you already know are safe to eat.

Why it matters

Investors are putting more money into companies that use AI in life sciences, and Wang’s reported fundraising talks fit that pattern. If AI helps researchers narrow down which drug ideas are worth testing, it could reduce time and cost before a medicine reaches patients, although any drug still needs careful lab work and clinical trials.

Source: TechCrunch AI